137 related articles for article (PubMed ID: 23815541)
1. Systemic therapies for malignant pheochromocytoma and paraganglioma can exacerbate hypertension.
Fishbein L; Cohen DL
J Clin Hypertens (Greenwich); 2013 Jul; 15(7):513-4. PubMed ID: 23815541
[No Abstract] [Full Text] [Related]
2. [Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].
Kukla U; Łabuzek K; Chronowska J; Bobrzyk M; Madej P; Okopień B
Pol Merkur Lekarski; 2015 Apr; 38(226):191-5. PubMed ID: 25938384
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors.
Toledo R; Jimenez C
F1000Res; 2018; 7():. PubMed ID: 30109021
[TBL] [Abstract][Full Text] [Related]
4. The role of pre-operative α-blockade in patients with normotensive phaeochromocytoma or paraganglioma: A retrospective cohort study.
Kong H; Li N; Li XY; Wang DX
Eur J Anaesthesiol; 2018 Nov; 35(11):898-899. PubMed ID: 30278035
[No Abstract] [Full Text] [Related]
5. Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.
Matro J; Giubellino A; Pacak K
Horm Metab Res; 2013 Feb; 45(2):147-53. PubMed ID: 23322515
[TBL] [Abstract][Full Text] [Related]
6. The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma.
Gruber LM; Jasim S; Ducharme-Smith A; Weingarten T; Young WF; Bancos I
J Clin Endocrinol Metab; 2021 May; 106(6):e2393-e2401. PubMed ID: 33693908
[TBL] [Abstract][Full Text] [Related]
7. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience.
Shilkrut M; Bar-Deroma R; Bar-Sela G; Berniger A; Kuten A
Am J Clin Oncol; 2010 Feb; 33(1):79-82. PubMed ID: 19704370
[TBL] [Abstract][Full Text] [Related]
8. Endocrine tumours.
Lamberts SW
Cancer Chemother Biol Response Modif; 1997; 17():492-503. PubMed ID: 9551228
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan.
Naruse M; Satoh F; Tanabe A; Okamoto T; Ichihara A; Tsuiki M; Katabami T; Nomura M; Tanaka T; Matsuda T; Imai T; Yamada M; Harada T; Kawata N; Takekoshi K
Endocr J; 2018 Mar; 65(3):359-371. PubMed ID: 29353821
[TBL] [Abstract][Full Text] [Related]
10. Niche for polyamine inhibition in treatment of metastatic pheochromocytoma and paraganglioma.
Ghayee HK; Hatch H; Bergeron RJ; Hadrava Vanova K; Pacak K; Tevosian S
Eur J Clin Invest; 2024 May; 54(5):e14162. PubMed ID: 38381501
[No Abstract] [Full Text] [Related]
11. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.
Niemeijer ND; Alblas G; van Hulsteijn LT; Dekkers OM; Corssmit EP
Clin Endocrinol (Oxf); 2014 Nov; 81(5):642-51. PubMed ID: 25041164
[TBL] [Abstract][Full Text] [Related]
12. Malignant pheochromocytoma and paraganglioma: three cases illustrating the use of molecular targeted diagnostics and therapy and possible role of new drugs.
Zukauskaite R; Hjorthgau K; Poulsen PL; Baerentzen S; Ladekarl M
Acta Oncol; 2011 Nov; 50(8):1255-9. PubMed ID: 21714698
[No Abstract] [Full Text] [Related]
13. Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG).
Porzig A; Matthay KK; Dubois S; Pampaloni M; Damon L; Hawkins R; Goldsby R; Hollinger F; Fitzgerald P
Horm Metab Res; 2012 Jun; 44(7):539-42. PubMed ID: 22588707
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapies for pheochromocytoma and paraganglioma.
Jimenez C; Fazeli S; Román-Gonzalez A
Endocr Relat Cancer; 2020 Jul; 27(7):R239-R254. PubMed ID: 32369773
[TBL] [Abstract][Full Text] [Related]
15. Prazosin in the diagnosis and treatment of pheochromocytoma.
Wallace JM; Gill DP
JAMA; 1978 Dec; 240(25):2752-3. PubMed ID: 713011
[TBL] [Abstract][Full Text] [Related]
16. Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines.
Powers JF; Korgaonkar PG; Fliedner S; Giubellino A; Pacak K; Sahagian GG; Tischler AS
PLoS One; 2014; 9(2):e87807. PubMed ID: 24516563
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma.
Ferrara AM; Lombardi G; Pambuku A; Meringolo D; Bertorelle R; Nardin M; Schiavi F; Iacobone M; Opocher G; Zagonel V; Zovato S
Anticancer Drugs; 2018 Jan; 29(1):102-105. PubMed ID: 29099418
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.
Tong A; Li M; Cui Y; Ma X; Wang H; Li Y
Front Endocrinol (Lausanne); 2020; 11():61. PubMed ID: 32132978
[No Abstract] [Full Text] [Related]
19. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
[TBL] [Abstract][Full Text] [Related]
20. Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.
Jimenez P; Tatsui C; Jessop A; Thosani S; Jimenez C
Curr Oncol Rep; 2017 Oct; 19(12):83. PubMed ID: 29081018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
